Drugs / Protexia
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00744146 | Sep 2008 → Jul 2009 | nerve agent poisoning | PharmAthene, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Protexia | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00744146 ↗ |
| Known as | PEG-rBChE | “Protexia is a pegylated form of recombinant human butyrylcholinesterase (PEG-rBChE).” NCT00744146 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human butyrylcholinesterase” NCT00744146 ↗ |
| Route | Intramuscular | “Protexia Administered Intramuscularly” NCT00744146 ↗ |